CO6331427A2 - Inhibodores de beta -lactamasa - Google Patents

Inhibodores de beta -lactamasa

Info

Publication number
CO6331427A2
CO6331427A2 CO10056779A CO10056779A CO6331427A2 CO 6331427 A2 CO6331427 A2 CO 6331427A2 CO 10056779 A CO10056779 A CO 10056779A CO 10056779 A CO10056779 A CO 10056779A CO 6331427 A2 CO6331427 A2 CO 6331427A2
Authority
CO
Colombia
Prior art keywords
beta
lactamasa
inhiboders
alpha
amino
Prior art date
Application number
CO10056779A
Other languages
English (en)
Inventor
Christopher John Burns
Randy W Jackson
Hongyu Xu
Rajesh Goswami
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO6331427A2 publication Critical patent/CO6331427A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

En la presente se dan a conocer ácidos alfa-amino-borónicos y sus derivados, los cuales actúan como inhibidores de beta-lactamasas. También, en la presente se dan a conocer composiciones farmacéuticas que comprenden ácidos alfa-amino-borónicos, y métodos de uso de las mismas.
CO10056779A 2007-11-13 2010-05-12 Inhibodores de beta -lactamasa CO6331427A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US279707P 2007-11-13 2007-11-13

Publications (1)

Publication Number Publication Date
CO6331427A2 true CO6331427A2 (es) 2011-10-20

Family

ID=40344560

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10056779A CO6331427A2 (es) 2007-11-13 2010-05-12 Inhibodores de beta -lactamasa

Country Status (21)

Country Link
US (2) US20100317621A1 (es)
EP (2) EP2220097A1 (es)
JP (2) JP2011504468A (es)
KR (2) KR20100109901A (es)
CN (2) CN101861324A (es)
AR (2) AR069310A1 (es)
AU (2) AU2008321444A1 (es)
BR (2) BRPI0820532A2 (es)
CA (2) CA2705393A1 (es)
CO (1) CO6331427A2 (es)
CR (1) CR11372A (es)
EA (2) EA201000774A1 (es)
EC (1) ECSP10010246A (es)
GT (1) GT201000143A (es)
IL (1) IL205205A0 (es)
MA (1) MA31874B1 (es)
MX (2) MX2010005250A (es)
TN (1) TN2010000203A1 (es)
TW (2) TW200936143A (es)
WO (2) WO2009064413A1 (es)
ZA (1) ZA201002467B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100120715A1 (en) * 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
US20100292185A1 (en) * 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors
AU2011289615B2 (en) 2010-08-10 2015-05-07 Melinta Therapeutics, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
JP6129203B2 (ja) * 2011-12-22 2017-05-17 アレス トレーディング ソシエテ アノニム α−アミノボロン酸誘導体、選択性免疫プロテアソーム阻害剤
CN104159587A (zh) * 2012-01-06 2014-11-19 南佛罗里达大学 组合物、使用方法、以及治疗方法
US8962843B2 (en) * 2012-03-30 2015-02-24 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN105026407B (zh) * 2012-12-07 2017-09-08 维纳拓尔斯制药公司 β‑内酰胺酶抑制剂
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2894892A1 (en) * 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
MX2015008628A (es) 2013-01-04 2015-09-23 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
WO2014110442A1 (en) 2013-01-10 2014-07-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP2970340B1 (en) * 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
PT3140310T (pt) 2014-05-05 2019-11-18 Rempex Pharmaceuticals Inc Síntese de sais de boronato e utilizações dos mesmos
WO2015179308A1 (en) 2014-05-19 2015-11-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP3882252A1 (en) * 2014-06-11 2021-09-22 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
KR20170024087A (ko) 2014-07-01 2017-03-06 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
KR102450583B1 (ko) * 2014-10-01 2022-10-04 메르크 파텐트 게엠베하 보론산 유도체
ES2811273T3 (es) * 2014-10-01 2021-03-11 Merck Patent Gmbh Derivados del ácido borónico
BR112017006349A2 (pt) * 2014-10-01 2017-12-12 Merck Patent Gmbh derivados de ácido borônico
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2016100043A1 (en) 2014-12-19 2016-06-23 Rempex Pharmaceuticals, Inc. Apparatus and continuous flow process for production of boronic acid derivatives
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP3347008B1 (en) 2015-09-11 2022-03-09 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
KR102512201B1 (ko) 2016-06-21 2023-03-20 오리온 옵탈몰로지 엘엘씨 지방족 프롤린아미드 유도체
PT3478693T (pt) 2016-06-30 2021-10-25 Qpex Biopharma Inc Derivados de ácido borónico e suas utilizações terapêuticas
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
US11091505B2 (en) 2017-03-06 2021-08-17 VenatoRx Pharmaceuticals, Inc. Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
EP3630783A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN BINDING PROTEIN INHIBITORS
CN110959008A (zh) 2017-05-26 2020-04-03 维纳拓尔斯制药公司 青霉素结合蛋白抑制剂
TW201906616A (zh) * 2017-07-06 2019-02-16 日商大日本住友製藥股份有限公司 醯胺衍生物
WO2019009369A1 (ja) * 2017-07-06 2019-01-10 大日本住友製薬株式会社 イミン誘導体
CN111212843A (zh) 2017-10-11 2020-05-29 Qpex生物制药有限公司 硼酸衍生物及其合成
WO2019204419A1 (en) 2018-04-20 2019-10-24 The Medicines Company (San Diego), Llc Boronic acid derivatives and therapeutic uses thereof
CA3121130A1 (en) * 2018-11-29 2020-06-04 VenatoRx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor and uses thereof
CN110156820B (zh) * 2019-04-25 2021-06-25 四川大学 一类巯基酰胺硼酸类衍生物及其作为mbl和/或sbl抑制剂的用途
CN114340639A (zh) 2019-06-19 2022-04-12 Qpex生物制药有限公司 硼酸衍生物及其治疗用途
CN113135944A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112572B2 (en) * 2002-09-09 2006-09-26 Trigen Limited Multivalent metal salts of boronic acids
US20060084592A1 (en) * 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
US7271186B1 (en) * 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
AU2004256841A1 (en) * 2003-06-10 2005-01-20 Fulcrum Pharmaceuticals, Inc. Beta-lactamase inhibitors and methods of use thereof
US20100120715A1 (en) * 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
US20100292185A1 (en) * 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors

Also Published As

Publication number Publication date
BRPI0820531A2 (pt) 2012-07-10
JP2011503181A (ja) 2011-01-27
TN2010000203A1 (en) 2011-11-11
EP2220096A1 (en) 2010-08-25
MX2010005252A (es) 2011-04-11
ZA201002467B (en) 2011-02-23
US20100286092A1 (en) 2010-11-11
CN101983203A (zh) 2011-03-02
TW200936143A (en) 2009-09-01
BRPI0820532A2 (pt) 2012-07-10
CN101861324A (zh) 2010-10-13
EA201000775A1 (ru) 2010-12-30
TW200930707A (en) 2009-07-16
US20100317621A1 (en) 2010-12-16
AR069463A1 (es) 2010-01-27
EP2220097A1 (en) 2010-08-25
CA2705393A1 (en) 2009-05-22
MA31874B1 (fr) 2010-11-01
AU2008321444A1 (en) 2009-05-22
WO2009064414A1 (en) 2009-05-22
EA201000774A1 (ru) 2010-12-30
CR11372A (es) 2010-09-14
AU2008321443A1 (en) 2009-05-22
KR20100109901A (ko) 2010-10-11
WO2009064413A1 (en) 2009-05-22
JP2011504468A (ja) 2011-02-10
IL205205A0 (en) 2010-12-30
AR069310A1 (es) 2010-01-13
CA2705389A1 (en) 2009-05-22
GT201000143A (es) 2012-04-30
MX2010005250A (es) 2010-11-05
ECSP10010246A (es) 2010-07-30
KR20100113485A (ko) 2010-10-21

Similar Documents

Publication Publication Date Title
CO6331427A2 (es) Inhibodores de beta -lactamasa
UY32626A (es) Inhibidores de beta-lactamasa
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
CR11427A (es) 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa
CR10148A (es) Derivados de las benzamidas y heteroarenos
HN2006035237A (es) Derivados de triazolopiridina en calidad de inhibidores de lipasas y fosfolipasas
CR20110216A (es) Derivados de ácido 1-amino-2-ciclobutiletilborónico
CR20110135A (es) INHIBIDORES DE cMET
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
UY32863A (es) COMPUESTOS DE HEXAHIDROOXAZINOPTERINA PARA USO COMO INHIBIDORES DE mTOR
UY30796A1 (es) 3-h-pirazolopiridinas y sales de éstas, composiciones farmacéuticas que las comprenden, métodos para prepararlas, y sus usos
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
ECSP099721A (es) Inhibidores de cinasa p70 s6
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
HN2007000267A (es) Compuestos de 4-metil piridopirimidinoma
CR11373A (es) COMPUESTOS DE TIENOPIRIMIDINA Y PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE mTOR CINASA Y PI3 CINASA
CR20110562A (es) Compuestos y métodos para la modulación de las quinasas e indicaciones de los mismos
CO6290656A2 (es) Derivados heterociclicos de urea y metodos de uso de los mismos -211
CR11826A (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato
DOP2011000076A (es) Derivados de heteroaril amidas y su uso como activadores de glucoquinasa
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
UY31456A1 (es) Derivados de 2-pirazinona como inhibidores de la elastasa de los neutrofilos
GT200900192A (es) Derivados de imidazol como inhibidores de proteina de uso de cinesina (eg-5).-

Legal Events

Date Code Title Description
FA Application withdrawn